BB Biotech (BION)

Last close As at 20/06/2024

CHF38.70

−0.10 (−0.26%)

Market capitalisation

CHF2,144m

BB Biotech, a Switzerland-based investment company, targets long-term capital growth from biotechnology companies developing and marketing innovative drugs. At least 90% of the portfolio is held in listed companies, primarily those that already have products on the market or promising drug candidates in advanced stages of development. BION is benchmarked against the Nasdaq Biotech Index (in CHF) but is managed on a bottom-up basis, with a focused c 20–35 stock portfolio.

Latest Insights

View More

Investment Companies | Review

BB Biotech — A recovering sector with a healthy prognosis

Investment Companies | Update

BB Biotech — A cutting-edge sector and a high dividend

Investment Companies | Update

BB Biotech — Picking growth at good value

Healthcare business concept, Medical examination and growth graph data of business on tablet with doctor's health report clipboard on background.

Equity Analyst

Joanne Collins

Joanne Collins

Analyst, Investment Trusts

Key Management

  • Claude Mikkelsen

    Director of IR

  • Daniel Koller

    Head of investment management

  • Dr Silvia Siegfried-Schanz

    Director of IR

  • Erich Hunziker

    Chairman

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (7.2) (17.5) (8.7)
Relative (7.4) (20.8) (14.4)
52 week high/low CHF49.4/CHF35.6

Overview

BB Biotech (BION) offers investors exposure to the innovative, rapidly expanding biotech sector. It is the largest biotech investor among its investment company peers, focused on high-quality biotech assets that target substantial market opportunities. BION’s performance has picked up in recent months, supported by an improvement in the market environment. Its managers are optimistic about the outlook as declines in interest rates, whenever they eventuate, begin to boost investor sentiment towards the sector, especially the mid- and small-cap companies that BION favours. The fund’s managers also expect ongoing progress by portfolio holdings, as several reach key milestones over the coming months. Unlike most of its peers, BION pays an attractive 5% dividend, calculated on average share price over December each year.

Review

Investment Companies

BB Biotech — High-conviction specialist with impressive record

Review

Investment Companies

BB Biotech — Update 27 February 2017

edison tv

Investment Companies

Bitesize Briefings – BB Biotech

Review

Investment Companies

BB Biotech AG — Update 8 February 2016